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Abstract
Background: Malignant bile duct obstruction is a common problem among cancer patients with hepatic or
lymphatic metastases. Endoscopic retrograde cholangiography (ERC) with the placement of a stent is the method
of choice to improve biliary flow. Only little data exist concerning the outcome of patients with malignant biliary
obstruction in relationship to microbial isolates from bile.
Methods: Bile samples were taken during the ERC procedure in tumor patients with biliary obstruction. Clinical
data including laboratory values, tumor-specific treatment and outcome data were prospectively collected.
Results: 206 ERC interventions in 163 patients were recorded. In 43 % of the patients, systemic treatment was (re-)
initiated after successful biliary drainage. A variety of bacteria and fungi was detected in the bile samples. One-year
survival was significantly worse in patients from whom multiresistant pathogens were isolated than in patients, in
whom other species were detected. Increased levels of inflammatory markers were associated with a poor one-year
survival. The negative impact of these two factors was confirmed in multivariate analysis.
In patients with pancreatic cancer, univariate analysis showed a negative impact on one-year survival in case of
detection of Candida species in the bile. Multivariate analysis confirmed the negative prognostic impact of Candida
in the bile in pancreatic cancer patients.
Conclusion: Outcome in tumor patients with malignant bile obstruction is associated with the type of microbial
biliary colonization. The proof of multiresistant pathogens or Candida, as well as the level of inflammation markers,
have an impact on the prognosis of the underlying tumor disease.
Keywords: Cancer, Pancreatic cancer, Biliary obstruction, Cholangitis, Chemotherapy, Systemic therapy
Background
Malignant biliary obstruction is a frequent complication in
patients with advanced tumor diseases. Both central hepatic
metastases and hilar lymph node metastases of gastrointes-
tinal and non-gastrointestinal cancers, but also tumors of
the pancreatic head often result in a biliary compression.
Obstructive jaundice is associated with increased
morbidity and mortality. Furthermore, intact bilirubin
excretion is mandatory for the administration of many
chemotherapeutical and targeted agents.
Only limited data exist concerning the role of jaundice in
patients with metastatic disease. In a retrospective study
published in 1994, median survival in patients with jaundice
due to metastatic colorectal cancer was approximately 3–5
months [1]. However, taking into consideration the increas-
ing number of therapeutic agents available for the treat-
ment of metastatic colorectal cancer, more therapeutic
options are available after improvement of biliary drainage,
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resulting in prolonged survival in patients. Furthermore, in
tumors being considered as chemorefractory such as hepa-
tocellular carcinoma (HCC), normalization of cholestasis
parameters is mandatory to initiate systemic targeted treat-
ment, such as sorafenib [2].
In patients with pancreatic carcinoma, biliary obstruction
occurs in approximately 70–90 % of all cases, possibly lead-
ing to a deterioration of the patients’ general condition due
to cholangitis, malabsorption or liver failure [3]. Although
surgical bypass has demonstrated a low rate of recurrent
jaundice, the surgical procedure itself carries a significant
risk of perioperative morbidity and mortality [4].
Endoscopic retrograde cholangiopancreatography (ERCP)
has been the preferred method for patients with malignant
biliary obstruction since the late 1980s. Studies showed an
equivalent success rate and decreased morbidity and mor-
tality for this method in comparison with percutaneous or
surgical approaches [5–7]. Yet, in patients with resectable
pancreatic cancer, immediate resection of the tumor with-
out a previous ERC is the preferred option [8].
Placement of a plastic or metal stent has been shown
to be an effective method in improving biliary flow.
Common complications include cholangitis and stent
occlusion, whereas pancreatitis is only rarely observed
post-ERCP [3]. The optimal type of stent (plastic or
metal) is still a matter of debate. Plastic stents have been
used as a standard method for biliary drainage; however,
regular stent exchange is necessary every 3–4 months in
order to prevent stent obstruction due to biliary sludge.
Thus, metal stents are preferred in patients with an ex-
pected survival of more than 3 to 4 months [9].
Development of a biofilm is a critical event in the
pathogenesis of cholangitis and the blockade of stents.
Effectiveness of antibiotic treatment is limited against
bacterial colonization of the biofilm [10].
The impact on biliary bacterial or mycotic infection in
tumor patients with malignant biliary obstruction on
survival is poorly studied. Data from patients undergoing
liver transplantation show a negative prognostic impact
on the proof of enteric bacteria or Candida species re-
garding time till organ failure [11–13].
In this prospective, observational study we aimed to
identify the spectrum of bactobilia and fungobilia in pa-
tients with malignant obstruction, and to explore the as-
sociation of this spectrum with clinical outcome.
Patients and methods
The prospective, observational study was conducted at
the Center for Endoscopy of the University Hospital
Heidelberg in collaboration with the Department of
Gastroenterology and the Department of Medical Oncology
at the National Center for Tumor Diseases, Heidelberg.
Patients were recruited consecutively. Data of patients
undergoing ERC for malignant biliary obstruction were
recorded in a prospective database. Biliary drainage was
performed whenever technically possible.
Bile samples were obtained after selective intubation
before any therapeutic procedure was performed. When
bile could not be aspirated directly after cannulation, a
small amount of sterile saline (2–4ml) was applied and
aspiration was reattempted. Aliquots of all biliary sam-
ples were placed in a sterile glass tube containing
medium for anaerobic and aerobic bacterial cultures.
The material was delivered to the microbiology labora-
tory within 2h of collection and cultured aerobically and
anaerobically according to standard laboratory protocols.
The underlying tumor disease including the stage of
the disease, the proof of bacteria or fungi, as well as la-
boratory values including bilirubin and C-reactive pro-
tein (CRP) at the time of intervention were recorded.
The previous or subsequent application of systemic ther-
apy (e.g. chemotherapy) was documented.
Assuming that the biliary infection would rather influ-
ence the short-term outcome whereas the long-term out-
come is determined by the underlying tumor disease,
patients’ outcome was followed for a maximum of one
year, patients lost to follow-up were censored at the time
of the last documented contact. All patients provided in-
formed consent, the study was performed in accordance
with the Declaration of Helsinki. The study was approved
by the ethical committee of the University of Heidelberg.
Table 1 Patient characteristics
Patient characteristics:
Number of patients: 163
Number of interventions: 206
Median age (range) 66 (36–96)
Tumor diagnosis Number of patients (%)
Pancreatic carcinoma 60 (37)
Cholangiocellular carcinoma 34 (21)
Colorectal carcinoma 19 (12)
Hepatocellular carcinoma 9 (6)
Gastric cancer 8 (5)
Breast cancer 8 (5)
Neuroendocrine tumor of the digestive tract 6 (4)
Tumor of unknown origin 5 (3)
Ovarian carcinoma 3 (2)
Intraductal papillary mucinous neoplasm (IPMN) 2 (1)
Lymphoma 1 (1)
Other tumors 8 (5)
Laboratory parameters before ERC Median (SD)
Bilirubin (mg/dl) 4.5 (6.83)
CRP (mg/l) 36.2 (62.11)
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ERCP was performed in an inpatient setting. Concur-
rent antibiotic treatment or peri-interventional prophy-
laxis were performed at the discretion of the responsible
physician.
Statistical analysis
Continuous data were compared using the nonparamet-
ric Mann–Whitney U test. Frequency differences were
compared using the chi-squared test or Fisher’s exact
test where appropriate. The actuarial survival rate was
estimated using the Kaplan-Meier product limit estima-
tor. Differences between the actuarial estimates were
tested using the log rank test. Cox regression analysis
was performed for multivariate analysis. Differences
were considered significant if p was <0.05. All analyses




Between October 2006 and December 2008, a total of
163 patients with advanced cancer diseases undergoing
ERC were recorded.
The most frequent tumors were advanced pancreatic
carcinoma (37 %), followed by cholangiocarcinoma (21 %)
and metastatic colorectal carcinoma (12 %). The median
age was 66 years (range 36–96 years). Patient characteris-
tics are shown in Table 1.
Among patients with pancreatic cancer, locally ad-
vanced disease was documented in 58 % of the cases,
metastatic disease in 42 %.
A total of 206 ERCP interventions were performed due
to suspected biliary obstruction. Biliary drainage with a
stent was performed in 143 interventions (69.4 %).
Microbiological results
Bacterial colonization of the bile was common; overall,
bacteria were detected in 128 samples (62 %). The most
commonly isolated species were Streptococcus species
(36 samples, 18 %), followed by Enterococcus species
Table 2 Microbial isolation
Organism Number of patients (%)
Bacteria
Streptococci, alpha- and beta-hemolytic 36 (18)
Enterococcus spp. 35 (17)
Escherichia coli 27 (13)
Coagulase-negative Staphylococcus 27 (13)
Klebsiella spp. 14 (7)
Clostridium 1 (1)
Other bacteria 45 (22)
Sterile bile 50 (24)
Missing data 28 (14)
Multiresistant bacteria
Vancomycin-resistant Enterococcus faecium 4 (2)
E. coli with extended spectrum beta-lactamase 4 (2)
Any multiresistant pathogen 14 (7)
Fungi
Candida albicans 32 (16)
Candida glabrata 11 (5)
Missing data 76 (37)
Fig. 1 One-year survival in tumor patients according to the microbial isolation of multiresistent (mr) pathogens
Haag et al. BMC Gastroenterology  (2015) 15:171 Page 3 of 7
(35 samples, 17 %) and Escherichia coli and coagulase-
negative Staphylococcus species (27 samples, 13 % respect-
ively) (Table 2).
Multiresistant gram-negative or gram-positive micro-
organisms, such as methicillin-resistant Staphylococcus
aureus or vancomycin-resistant Enterococcus, were only
rarely observed; these were detected in 14 samples (7 %).
Mycologic results were available for 130 interventions.
Candida albicans was detected in 32 samples (16 %) and
Candida glabrata was detected in 11 samples (5 %).
Among patients with previous ERC, a significantly in-
creased risk of a fungal biliary colonization was observed
(10 of 73 patients without previous ERC vs. 33 of 62 pa-
tients with previous ERC, p <0.001).
Patients with proven fungobilia had a significantly lon-
ger period of antibiotic therapy before ERC intervention
(median 6 days vs. 3 days; p = 0.020).
Clinical outcome
In our series, patient outcome was associated with the
microbial pathogens involved and the inflammatory state
prior to ERC intervention.
Patients with a multiresistant pathogen isolated in bile
during the first ERC intervention had a significantly worse
one-year survival than patients without finding of a multi-
resistant species (One year survival rate 55.8 % vs. 16.7 %,
p = 0.001) (Fig. 1).
Malignant obstruction, the resulting increased risk of
cholangitis, and the advanced tumor diseases themselves
can all contribute to a permanent state of inflammation.
Distinguishing patients with a tumor-related inflamma-
tory state from those with bacterial infection can be a
clinical challenge. In our series, tumor patients present-
ing with increased levels of inflammatory markers at the
first ERC intervention, defined by a C-reactive protein
level higher than 25 mg/l (normal range, 0.5–5 mg/l),
had a significantly worse one-year survival than patients
without increased inflammation markers (One year sur-
vival rate 64.8 % vs. 46.0 %, p = 0.002) (Fig. 2).
Multivariate analysis including age (less or more than
65 years), the proof of any multiresistant pathogen, the
proof of Candida species, placement of a stent, the pri-
mary tumor (pancreatic vs. non-pancreatic), a high biliru-
bin level (higher than 7 mg/dl) and a high CRP level
(higher than 25 mg/l) confirmed the negative impact of a
multiresistent pathogen (Hazard Ratio 8.77, p = 0.009) or
a high CRP level (Hazard Ratio 2.98, p = 0.041) (Table 3).
Among patients with pancreatic cancer, those in whom
Candida species was found at the first ERC intervention
Fig. 2 One-year survival in tumor patients according to preinterventional C-reactive protein level





Placement of Stent (yes vs. noa) 0.245 2.12 [0.60;7.55]
Pancreatic primary tumor (yes vs. noa) 0.714 1.22 [0.43;3.50]
Bilirubin (≥7 mg/dl vs. <7 mg/dla) 0.321 0.58 [0.20;1.69]
Age (≥65 years vs. <65 yearsa) 0.245 0.56 [0.21;1.49]
Proof of candida (yes vs. noa) 0.709 1.19 [0.47;3.04]
Proof of multiresistant pathogen
(yes vs. noa)
0.009 8.77 [1.70;45.17]
CRP (≥25 mg/l vs. <25 mg/la) 0.041 2.98 [1.05;8.50]
areference
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had a significantly lower one-year survival than patients
without findings of Candida in bile (One year survival
rate 80.8 % vs. 35.4 %, p = 0.044) in univariate analysis
(Fig. 3). Additionally, the pre-interventional bilirubin
and C-reactive protein level at the first intervention did
not differ significantly between these 2 groups.
Multivariate analysis including the proof of Candida
species, placement of a stent, tumor stage (locally advanced
vs. metastatic disease), a high bilirubin level (higher than
7 mg/dl) and a high CRP level (higher than 25 mg/l) con-
firmed the negative prognostic impact of the proof of Can-
dida in the bile. (Hazard Ratio 23.07, p= 0.049) (Table 4).
Previous and further tumor-specific treatment
59 patients (36 %) presenting with advanced disease had
received previous systemic therapy for their tumor disease,
which had to be discontinued because of progressive jaun-
dice. After the intervention, tumor-specific systemic treat-
ment was (re)-initiated in 70 patients (43 %), after the
malignant obstruction was alleviated due to successful
drainage (Table 5).
The prevalence of candida did not differ between pan-
creatic cancer patients with or without previous systemic
chemotherapy (p = 0.661); in addition there was no statis-
tical difference with regard to fungobilia in the rate of pa-
tients undergoing systemic treatment after successful ERC
intervention (p = 0.631) or in the time till (re-)initiation of
systemic chemotherapy (p = 0.161).
Discussion
Data concerning the optimal management and outcome
of patients with malignant bile duct obstruction are
limited. For more than 20 years, ERC has been the
method of choice to improve biliary drainage. Early inter-
vention is desirable to prevent secondary complications
such as liver failure or cholangitis. Additionally, an in-
crease in the performance score can often be observed
after relief of jaundice.
In our series, the detected bacterial species were com-
mon pathogens, which could be controlled with standard
antibiotic treatment. In contrast to other cohorts (e.g. pa-
tients who underwent liver transplantation [11–13]) , mul-
tiresistant bacteria were only rarely observed, but these
patients had a significantly worse outcome.
Among all cancer patients, those with increased C-
reactive protein levels had a significantly worse outcome
than those with low levels of inflammatory markers. In
concordance to our data Iwasaki et al. showed that an
inflammation-based prognostic score (mGPS, modified
Glasgow Prognostic Score) including C-reactive protein
and hypalbuminemia is a significant predictor of postop-
erative survival in patients undergoing palliative surgery
for malignant biliary obstruction [14]. It is unknown





Placement of Stent (yes vs. noa) 0.830 0.80 [0.11;5.90]
Bilirubin (≥7 mg/dl vs. <7 mg/dla) 0.982 0.98 [0.14;6.78]
Proof of candida (yes vs. noa) 0.049 23.07 [1.01;526.64]
CRP (≥25 mg/l vs. <25 mg/la) 0.293 0.25 [0.02;3.31]
metastatic vs. locally adv. diseasea 0.108 8.92 [0.62;128.38]
areference
Fig. 3 One-year survival in patients with pancreatic cancer according to the proof of Candida sp.
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whether these increased markers are a sign of a more se-
vere bacterial cholangitis or the result of a tumor-related
inflammatory status due to a more advanced disease.
Other more specific markers like procalcitonin could be
useful in distinguishing between a bacterial infection and
a tumor-related inflammatory state [15].
The prognostic role of fungi detected in the bile of pa-
tients with malignant biliary obstruction is not yet well
defined. In our series, Candida species was detected in
approximately 25 % of all pancreatic cancer patients; if
Candida species was detected in the bile, the patients
had a significantly worse one-year survival than those in
whom Candida was not detected. The negative prognos-
tic impact was confirmed in multivariate analysis. The
reason for this effect is unknown; proof of Candida was
neither associated with previous immunosuppressive ther-
apy (cytotoxic chemotherapy) nor with increased levels of
inflammatory markers or cholestasis parameters. These
findings were in contrast to those for the rest of the pa-
tients who had malignant jaundice. No significant differ-
ence was noted in the rate of Candida detection between
the groups with locally advanced and metastatic cancer.
Candida might therefore have a negative impact on out-
come in patients with pancreatic cancer and malignant
biliary obstruction. A randomized trial with antimycotic
treatment in this cohort might help in defining the path-
ognomonic role of this species in the bile.
With regard to previous and post-interventional tumor-
specific therapy, more than one-third of our patients had
received previous tumor-specific medical therapy, which
had to be discontinued because of tumor progression with
obstructive jaundice. After the ERC intervention, a start
or re-initiation of tumor-specific therapy is documented
to have occurred in 43 % of patients, highlighting the wid-
ening oncological therapeutic options once the biliary
drainage is improved.
Conclusions
In summary, endoscopic intervention for cancer patients
is a feasible and effective method of improving biliary
drainage. It should be performed as soon as malignant
obstruction is diagnosed in order to permit the start or
continuation of tumor-specific therapy. The bacterial spe-
cies found in the bile of cancer patients were mostly com-
mon pathogens, which could be controlled with standard
antibiotic treatment.
Our data showed a negative impact of Candida on one-
year survival in patients with pancreatic cancer. Whether
an antimycotic treatment could overcome this negative
outcome is unknown. Thus, the role of Candida in the
bile should be explored in a randomized trial.
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